clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2024-102-8-585-592clinmed-914Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESВозможности мРНК-терапии в лечении сердечно-сосудистых заболеванийPotential of mRNA therapy in the treatment of cardiovascular diseaseshttps://orcid.org/0000-0003-4973-039XАйтбаевК. А.AitbaevK. A.

Айтбаев Кубаныч Авенович — д-р мед. наук, профессор, зав. лабораторией патологической физиологии и иммунологии; член правления Общества специалистов по хронической болезни почек Кыргызстана

Бишкек

Kubanych A. Aitbaev — Doctor of Medical Sciences, Professor, Head of the Laboratory of Pathological Physiology and Immunology; Member of the Board of the Society of Specialists in Chronic Kidney Disease of Kyrgyzstan

Bishkek

https://orcid.org/0000-0001-8513-9279МуркамиловИ. Т.MurkamilovI. T.

Муркамилов Илхом Торобекович — д-р мед. наук, доцент кафедры факультетской терапии; профессор кафедры терапии №2 медицинского факультета; председатель правления Общества специалистов по хронической болезни почек Кыргызстана

Бишкек

Ilkhom T. Murkamilov — Doctor of Medical Sciences, Associate Professor of the Department of Faculty Therapy; Professor of the Department of Therapy No. 2 of the Medical Faculty; Chairman of the Board of the Society of Specialists in Chronic Kidney Disease of Kyrgyzstan

Bishkek

murkamilov.i@mail.ruhttps://orcid.org/0000-0002-2682-4417ФоминВ. В.FominV. V.

Фомин Виктор Викторович — д-р мед. наук, профессор, член-корр. РАН, зав. кафедрой факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского, проректор по инновационной и клинической деятельности

Москва

Viktor V. Fomin — Doctor of Medical Sciences, Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Faculty Therapy No. 1 of the N.V. Sklifosovsky Institute of Clinical Medicine, Vice-Rector for Innovation and Clinical Activities

Moscow

Научно-исследовательский институт молекулярной биологии и медициныКыргызстанScientific and Research Institute of Molecular Biology and MedicineKyrgyzstanКыргызская государственная медицинская академия им. И.К. Ахунбаева; ГОУ ВПО «Кыргызско-Российский Славянский университет имени первого Президента Российской Федерации Б.Н. Ельцина»КыргызстанI.K. Akhunbaev Kyrgyz State Medical Academy; Kyrgyz-Russian Slavic University named after the First President of the Russian Federation B.N. YeltsinKyrgyzstanФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russia (Sechenov University)Russian Federation2024090120251028585592Copyright © Айтбаев К.А., Муркамилов И.Т., Фомин В.В., 20252025Айтбаев К.А., Муркамилов И.Т., Фомин В.В.Aitbaev K.A., Murkamilov I.T., Fomin V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/914

Вспышка коронавирусной инфекции в 2019 г. (COVID-19), вызванная коронавирусом тяжелого острого респираторного синдрома 2 (SARS-CoV-2), встревожила мировое сообщество большим количеством унесенных пандемией человеческих жизней . Положительным аспектом этой недавней пандемии стало то, что она, стимулировав ученых на создание вакцин против SARS-CoV-2, ускорила появление новейших терапевтических средств на основе матричных (информационных) рибонуклеиновых кислот (мРНК). В настоящее время разрабатывается множество мРНК-терапевтических препаратов, десятки из них находятся на различных стадиях клинических испытаний. Эти препараты способствовали кардинальным изменениям в парадигме медицинской терапии, в том числе в лечении сердечно-сосудистых заболеваний (ССЗ). Хотя большинство из этих сердечно-сосудистых мРНК-терапевтических средств все еще находится в стадии доклинической разработки, тем не менее испытания фазы IIа мРНК-терапии ишемии миокарда уже завершены с обнадеживающими результатами. Спектр применения мРНК-терапии при ССЗ чрезвычайно широк, можно даже сказать — безграничен, а текущие исследования по мРНК-терапии включают такие патологические состояния как ишемия миокарда, сердечная недостаточность, аритмии, гиперхолестеринемия и окклюзионные заболевания артерий. Кроме того, мРНК могут быть использованы для повышения эффективности клеточной терапии. В будущем мРНК-терапии суждено, по мнению исследователей, не только вытеснить некоторые из существующих биопрепаратов и способов фармакотерапии, но и найти применение для лечения ССЗ, ранее считавшихся не поддающимися традиционным методам лечения.

The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), alarmed the global community due to the significant loss of human lives during the pandemic. However, as the saying goes, every cloud has a silver lining. A positive aspect of this recent pandemic has been that it stimulated scientists to create vaccines against SARS-CoV-2, accelerating the emergence of new therapeutic agents based on messenger ribonucleic acid (mRNA). Numerous mRNA therapeutic products are currently in development, with dozens at various clinical trial stages. These products have facilitated significant changes in the paradigm of medical therapy, including the treatment of cardiovascular diseases (CVD). Although most of these cardiovascular mRNA therapeutics are still in preclinical development, phase IIa trials for myocardial ischemia therapy have already been completed with encouraging results. The scope of mRNA therapy for CVD is extremely broad, potentially even limitless, with ongoing research including conditions like myocardial ischemia, heart failure, arrhythmias, hypercholesterolemia, and occlusive arterial diseases. Moreover, mRNA can be used to enhance the effectiveness of cell therapies. In the future, researchers predict that mRNA therapies will not only replace some existing biopharmaceuticals and pharmacotherapy methods but also be applied to treat previously considered untreatable cardiovascular diseases.

мРНК-терапияинфаркт миокардасердечная недостаточностьаритмиигиперхолестеринемиястарениетеломеразаперсонализированная медицинаmRNA therapymyocardial infarctionheart failurearrhythmiashypercholesterolemiaagingtelomerasepersonalized medicineReferencesSasso J.M., Ambrose B.J.B., Tenchov R. et al. The progress and promise of RNA medicine — an arsenal of targeted treatments. J. Med. Chem. 2022;65(10):6975–7015. DOI: 10.1021/acs.jmedchem.2c00024. Epub 2022 May 9. PMID: 35533054; PMCID: PMC9115888.Sasso J.M., Ambrose B.J.B., Tenchov R. et al. The progress and promise of RNA medicine — an arsenal of targeted treatments. J. Med. Chem. 2022;65(10):6975–7015. DOI: 10.1021/acs.jmedchem.2c00024. Epub 2022 May 9. PMID: 35533054; PMCID: PMC9115888.Zogg H., Singh R., Ro S. Current advances in RNA therapeutics for human diseases. Int. J. Mol. Sci. 2022;23(5):2736. DOI: 10.3390/ijms23052736. PMID: 35269876; PMCID: PMC8911101.Zogg H., Singh R., Ro S. Current advances in RNA therapeutics for human diseases. Int. J. Mol. Sci. 2022;23(5):2736. DOI: 10.3390/ijms23052736. PMID: 35269876; PMCID: PMC8911101.Collén A., Bergenhem N., Carlsson L. et al. VEGFA mRNA for regenerative treatment of heart failure. Nat. Rev. Drug. Discov. 2022;21(1):79–80. DOI: 10.1038/s41573-021-00355-6Collén A., Bergenhem N., Carlsson L. et al. VEGFA mRNA for regenerative treatment of heart failure. Nat. Rev. Drug. Discov. 2022;21(1):79–80. DOI: 10.1038/s41573-021-00355-6Center for RNA Therapeutics. 2022. [cited 2022 Oct 21]. [Electronic resource]. URL: www.houstonmethodist.org/rna-therapeuticsCenter for RNA Therapeutics. 2022. [cited 2022 Oct 21]. [Electronic resource]. URL: www.houstonmethodist.org/rna-therapeuticsFDA Takes Key Action in fi ght against COVID-19 by issuing emergency use authorization for fi rst COVID-19 vaccine. 2020. [cited 2022 Oct 24]. [Electronic resource]. URL: https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19FDA Takes Key Action in fi ght against COVID-19 by issuing emergency use authorization for fi rst COVID-19 vaccine. 2020. [cited 2022 Oct 24]. [Electronic resource]. URL: https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19CEPI 2.0 and the 100 days mission. 2022. [cited 2022 Oct 24]. [Electronic resource]. URL: https://100days.cepi.net/CEPI 2.0 and the 100 days mission. 2022. [cited 2022 Oct 24]. [Electronic resource]. URL: https://100days.cepi.net/Terada Y., Kawachi K., Matsuura Y., Kamitani W. MERS coronavirus nsp1 participates in an effi cient propagation through a specifi c interaction with viral RNA. Virology. 2017;511:95–105. DOI: 10.1016/j.virol.2017.08.026Terada Y., Kawachi K., Matsuura Y., Kamitani W. MERS coronavirus nsp1 participates in an effi cient propagation through a specifi c interaction with viral RNA. Virology. 2017;511:95–105. DOI: 10.1016/j.virol.2017.08.026Shehata M.M., Kandeil A., Mostafa A. et al. A recombinant infl uenza A/H1N1 carrying a short immunogenic peptide of MERS-CoV as bivalent vaccine in BALB/c mice. Pathogens. 2019;8(4):281. DOI: 10.3390/pathogens8040281Shehata M.M., Kandeil A., Mostafa A. et al. A recombinant infl uenza A/H1N1 carrying a short immunogenic peptide of MERS-CoV as bivalent vaccine in BALB/c mice. Pathogens. 2019;8(4):281. DOI: 10.3390/pathogens8040281Karikó K., Buckstein M., Ni H., Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modifi cation and the evolutionary origin of RNA. Immunity. 2005;23(2):165–75. DOI: 10.1016/j.immuni.2005.06.008Karikó K., Buckstein M., Ni H., Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modifi cation and the evolutionary origin of RNA. Immunity. 2005;23(2):165–75. DOI: 10.1016/j.immuni.2005.06.008Geall A.J., Verma A., Otten G.R. et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. USA. 2012;109(36):14604–9. DOI: 10.1073/pnasGeall A.J., Verma A., Otten G.R. et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. USA. 2012;109(36):14604–9. DOI: 10.1073/pnasStewart D.J., Kutryk M.J.B., Fitchett D. et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol. Ther. 2009;17(6):1109–15. DOI: 10.1038/mt.2009.70Stewart D.J., Kutryk M.J.B., Fitchett D. et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol. Ther. 2009;17(6):1109–15. DOI: 10.1038/mt.2009.70Stewart D.J., Hilton J.D., Arnold J.M.O. et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther. 2006;13(21):1503–11. DOI: 10.1038/sj.gt.3302802Stewart D.J., Hilton J.D., Arnold J.M.O. et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther. 2006;13(21):1503–11. DOI: 10.1038/sj.gt.3302802Zangi L., Lui K.O., von Gise A. et al. Modifi ed mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat. Biotechnol. 2013;31(10):898–907. DOI: 10.1038/nbt.2682Zangi L., Lui K.O., von Gise A. et al. Modifi ed mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat. Biotechnol. 2013;31(10):898–907. DOI: 10.1038/nbt.2682Gan L.M., Lagerström-Fermér M., Carlsson L.G. et al. Intradermal delivery of modifi ed mRNA encoding VEGF-A in patients with type 2 diabetes. Nat. Commun. 2019;10(1):871. DOI: 10.1038/s41467-019-08852-4Gan L.M., Lagerström-Fermér M., Carlsson L.G. et al. Intradermal delivery of modifi ed mRNA encoding VEGF-A in patients with type 2 diabetes. Nat. Commun. 2019;10(1):871. DOI: 10.1038/s41467-019-08852-4Anttila V., Saraste A., Knuuti J. et al. Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial. Mol. Ther. Methods Clin. Dev. 2020;18:464–472. DOI: 10.1016/j.omtm.2020.05.030Anttila V., Saraste A., Knuuti J. et al. Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial. Mol. Ther. Methods Clin. Dev. 2020;18:464–472. DOI: 10.1016/j.omtm.2020.05.030Liu S., Tang L., Zhao X. et al. Yap Promotes Noncanonical Wnt Signals From Cardiomyocytes for Heart Regeneration. Circ. Res. 2021;129(8):782–797. DOI: 10.1161/CIRCRESAHA.121.318966Liu S., Tang L., Zhao X. et al. Yap Promotes Noncanonical Wnt Signals From Cardiomyocytes for Heart Regeneration. Circ. Res. 2021;129(8):782–797. DOI: 10.1161/CIRCRESAHA.121.318966Kapoor N., Liang W., Marbán E., Cho H.C. Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18. Nat. Biotechnol. 2013;31(1):54–62. DOI: 10.1038/nbt.2465Kapoor N., Liang W., Marbán E., Cho H.C. Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18. Nat. Biotechnol. 2013;31(1):54–62. DOI: 10.1038/nbt.2465Choudhury M., Black N., Alghamdi A. et al. TBX18 overexpression enhances pacemaker function in a rat subsidiary atrial pacemaker model of sick sinus syndrome. J. Physiol. 2018;596(24):6141–6155. DOI: 10.1113/JP276508. Epub 2018 Oct 13. PMID: 30259525; PMCID: PMC6292813Choudhury M., Black N., Alghamdi A. et al. TBX18 overexpression enhances pacemaker function in a rat subsidiary atrial pacemaker model of sick sinus syndrome. J. Physiol. 2018;596(24):6141–6155. DOI: 10.1113/JP276508. Epub 2018 Oct 13. PMID: 30259525; PMCID: PMC6292813Bai Y., Kan S., Zhou S. et al. Enhancement of the in vivo persistence and antitumor effi cacy of CD19 chimeric antigen receptor T cells through the delivery of modifi ed TERT mRNA. Cell. Discov. 2015;1:15040. DOI: 10.1038/celldisc.2015.40Bai Y., Kan S., Zhou S. et al. Enhancement of the in vivo persistence and antitumor effi cacy of CD19 chimeric antigen receptor T cells through the delivery of modifi ed TERT mRNA. Cell. Discov. 2015;1:15040. DOI: 10.1038/celldisc.2015.40Li Y., Zhou G., Bruno I.G. et al. Transient introduction of human telomerase mRNA improves hallmarks of progeria cells. Aging Cell. 2019;18(4):e12979. DOI: 10.1111/acel.12979Li Y., Zhou G., Bruno I.G. et al. Transient introduction of human telomerase mRNA improves hallmarks of progeria cells. Aging Cell. 2019;18(4):e12979. DOI: 10.1111/acel.12979Mojiri A., Walther B.K., Jiang C. et al. Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice. Eur. Heart J. 2021;42(42):4352-4369. DOI: 10.1093/eurheartj/ehab547Mojiri A., Walther B.K., Jiang C. et al. Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice. Eur. Heart J. 2021;42(42):4352-4369. DOI: 10.1093/eurheartj/ehab547Chang D.F., Court K.A., Holgate R. et al. Telomerase mRNA enhances human skin engraftment for wound healing. Adv. Healthc. Mater. 2023;24:e2302029. DOI: 10.1002/adhm.202302029. Epub ahead of print. PMID: 37619534.Chang D.F., Court K.A., Holgate R. et al. Telomerase mRNA enhances human skin engraftment for wound healing. Adv. Healthc. Mater. 2023;24:e2302029. DOI: 10.1002/adhm.202302029. Epub ahead of print. PMID: 37619534.Dzul-Huchim V.M., Ramirez-Sierra M.J., Martinez-Vega P.P. et al. Vaccine-linked chemotherapy with a low dose of benznidazole plus a bivalent recombinant protein vaccine prevents the development of cardiac fi brosis caused by Trypanosoma cruzi in chronically-infected BALB/c mice. PLoS Negl. Trop. Dis. 2022;16(9):e0010258. DOI: 10.1371/journal.pntd.0010258Dzul-Huchim V.M., Ramirez-Sierra M.J., Martinez-Vega P.P. et al. Vaccine-linked chemotherapy with a low dose of benznidazole plus a bivalent recombinant protein vaccine prevents the development of cardiac fi brosis caused by Trypanosoma cruzi in chronically-infected BALB/c mice. PLoS Negl. Trop. Dis. 2022;16(9):e0010258. DOI: 10.1371/journal.pntd.0010258Kim S.C., Stice J.P., Chen L. et al. Extracellular heat shock protein 60, cardiac myocytes, and apoptosis. Circ. Res. 2009;105(12):1186– 95. DOI: 10.1161/CIRCRESAHA.109.209643Kim S.C., Stice J.P., Chen L. et al. Extracellular heat shock protein 60, cardiac myocytes, and apoptosis. Circ. Res. 2009;105(12):1186– 95. DOI: 10.1161/CIRCRESAHA.109.209643Youker K.A., Shen H., Bhimaraj A., Torre-Amione G. Abstract 11435: A new paradigm in therapy: a vaccine against the progression of heart failure. Circulation. 2021;144(1):A11435. DOI: 10.1161/circ.144.suppl_1.11435Youker K.A., Shen H., Bhimaraj A., Torre-Amione G. Abstract 11435: A new paradigm in therapy: a vaccine against the progression of heart failure. Circulation. 2021;144(1):A11435. DOI: 10.1161/circ.144.suppl_1.11435Vogel A.B., Lambert L., Kinnear E. et al. Self-amplifying RNA vaccines give equivalent protection against infl uenza to mRNA vaccines but at much lower doses. Mol. Ther. 2018;26(2):446–455. DOI: 10.1016/j.ymthe.2017.11.017Vogel A.B., Lambert L., Kinnear E. et al. Self-amplifying RNA vaccines give equivalent protection against infl uenza to mRNA vaccines but at much lower doses. Mol. Ther. 2018;26(2):446–455. DOI: 10.1016/j.ymthe.2017.11.017Beissert T., Perkovic M., Vogel A. et al. A Trans-amplifying RNA vaccine strategy for induction of potent protective immunity. Mol. Ther. 2020;28(1):119-128. DOI: 10.1016/j.ymthe.2019.09.009Beissert T., Perkovic M., Vogel A. et al. A Trans-amplifying RNA vaccine strategy for induction of potent protective immunity. Mol. Ther. 2020;28(1):119-128. DOI: 10.1016/j.ymthe.2019.09.009Lu D., Chatterjee S., Xiao K. et al. A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity. Eur. Heart J. 2022;43(42):4496–4511. DOI: 10.1093/eurheartj/ehac337Lu D., Chatterjee S., Xiao K. et al. A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity. Eur. Heart J. 2022;43(42):4496–4511. DOI: 10.1093/eurheartj/ehac337Boada C., Zinger A., Tsao C. et al. Rapamycin-loaded biomimetic nanoparticles reverse vascular infl ammation. Circ. Res. 2020;126(1):25–37. DOI: 10.1161/CIRCRESAHA.119Boada C., Zinger A., Tsao C. et al. Rapamycin-loaded biomimetic nanoparticles reverse vascular infl ammation. Circ. Res. 2020;126(1):25–37. DOI: 10.1161/CIRCRESAHA.119Rurik J.G., Epstein J.A. Uniting disciplines to develop therapeutics: targeted mRNA lipid nanoparticles reprogram the immune system in vivo to treat heart disease. DNA Cell. Biol. 2022;41(6):539–543. DOI: 10.1089/dna.2022.0171Rurik J.G., Epstein J.A. Uniting disciplines to develop therapeutics: targeted mRNA lipid nanoparticles reprogram the immune system in vivo to treat heart disease. DNA Cell. Biol. 2022;41(6):539–543. DOI: 10.1089/dna.2022.0171Rurik J.G., Tombácz I., Yadegari A. et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91–96. DOI: 10.1126/science.abm0594. PMID: 34990237; PMCID: PMC9983611.32.Rurik J.G., Tombácz I., Yadegari A. et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91–96. DOI: 10.1126/science.abm0594. PMID: 34990237; PMCID: PMC9983611.32.

The authors declare that there are no conflicts of interest present.